ArticleJournal of general internal medicine2019
Increasing the Precision of Hypertension Treatment Through Personalized Trials: a Pilot Study.
Article in Journal of general internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02744456 (A Pilot Study of N-of-1 Trials of Blood Pressure Medications in Adults With Hypertension), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study of N-of-1 Trials of Blood Pressure Medications in Adults With Hypertension
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Acupressure and hypnosis in arterial hypertension: a series of N-of-1 trials.Frontiers in medicine · 2026Trial
- N-of-1 Trials vs. Usual Care in Children With Hypertension: A Pilot Randomized Clinical Trial.American journal of hypertension · 2023Trial
- Controversy in Hypertension: Pro-Side of the Argument Using Artificial Intelligence for Hypertension Diagnosis and Management.Hypertension (Dallas, Tex. : 1979) · 2025Review
- Alleviating the public health burden of hypertension: debating precision prevention as a possible solution.Global health action · 2024Article
- Power analysis for idiographic (within-subject) clinical trials: Implications for treatments of rare conditions and precision medicine.Behavior research methods · 2023Article
- Precision Medicine and the future of Cardiovascular Diseases: A Clinically Oriented Comprehensive Review.Journal of clinical medicine · 2023Review
- Lessons for Understanding Central Nervous System HIV Reservoirs from the Last Gift Program.Current HIV/AIDS reports · 2022Review
- N-of-1 trials to facilitate evidence-based deprescribing: Rationale and case study.British journal of clinical pharmacology · 2022Review
- Evaluating Personalized (N-of-1) Trials in Rare Diseases: How Much Experimentation Is Enough?Harvard data science review · 2022Article
- N-of-1 Trials in Pediatric Oncology: From a Population-Based Approach to Personalized Medicine-A Review.Cancers · 2021Review
- Racial and ethnic minority patient participation in N-of-1 trials: perspectives of healthcare providers and patients.Personalized medicine · 2021Article
- Experimental Designs to Optimize Treatments for Individuals: Personalized N-of-1 Trials.JAMA pediatrics · 2021Article
- Repurposing approved drugs for cancer therapy.British medical bulletin · 2021Review
- Personal preferences for Personalised Trials among patients with chronic diseases: an empirical Bayesian analysis of a conjoint survey.BMJ open · 2020Article
- Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety.PloS one · 2020Article
- N-of-1 Trials in Hypertension Are Feasible, but Are They Worthwhile?Journal of general internal medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThere are substantial differences in the effects of blood pressure (BP) medications in individual patients. Yet, the current standard approach to prescribing BP medications is not personalized.
objectiveTo determine the feasibility of individualizing the selection of BP medications through pragmatic personalized (i.e., N-of-1) trials.
designSeries of N-of-1 trials.
settingOutpatient. PATIENTS: Hypertensive adults prescribed none or one BP medication.
interventionParticipation in a flexible, open-label personalized trial of two to three BP medications (NCT02744456). MEASUREMENTS: BP was measured twice per day with a validated home BP device. Frequency and severity of side effects were assessed at the end of the day via an electronic questionnaire. Patients' BP medication preference was assessed after reviewing BP lowering and side effect results with a study clinician. Feasibility was assessed by determining the proportion of patients who adhered to self-assessments. Benefit was assessed by asking patients to rate the helpfulness of participation and whether they would recommend personalized trials to other hypertensive patients. KEY
resultsOf ten patients enrolled, two dropped out prior to initiation, one discovered white coat hypertension through ambulatory BP monitoring, and seven (mean age 58 years, 71% of women) completed personalized trials. All seven were compliant with home BP monitoring and side effect tracking. All seven recommended personalized trials of BP medications to others. Thiazides were preferred by three patients, renin-angiotensin system-blocking agents by two patients, a combination of thiazide and beta-blocker by one patient, and any of three classes by one patient.
conclusionsPersonalized trials of BP medications were feasible and led to improved treatment precision. Heterogeneity of patient preferences and of therapeutic BP response for first-line BP medications can be determined through a personalized trial approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.